Executive Medical Director, Immunology – Early Clinical

100 Eli Lilly and Company; Boston (MA); On-site; USD 266,000 - 389,000; Full time

Benefits offered by this job

401(k) plan

Comprehensive benefits

Job summary

Lilly seeks an accomplished physician-scientist to join its Immunology team as Executive Medical Director, Early Clinical Development. This role bridges discovery science with early development, driving transformational medicines for autoimmune and inflammatory diseases.

The successful candidate leads cross-functional teams, shapes portfolio strategy, and accelerates first‑in‑human programs toward proof‑of‑concept, with strong executive presence and collaboration across discovery, translational

Qualifications

• Medical Doctor or Doctor of Osteopathy with board eligibility/certification.
• Experience in early clinical development, translational medicine and biomarker development.
• Strong cross-functional collaboration and matrix leadership.
• Knowledge of regulatory requirements for early clinical development (IND strategy, FDA interactions).

Responsibilities

• Strategic portfolio leadership across autoimmune/inflammatory diseases within immunology.
• Design and oversee early clinical studies with cross-functional teams.
• Integrate translational endpoints and biomarker strategies to accelerate learning.
• Contribute to regulatory interactions and global development planning (IND strategy).
• Mentor and develop junior team members; build scientific capabilities.

Education

MD/DO Medical degree

Board eligibility/certification

PhD in Immunology or Molecular Biology

Advanced degree in clinical research/pharmaceutical medicine

Job description

Lilly seeks an accomplished physician-scientist to join its Immunology team as Executive Medical Director, Early Clinical Development. This role bridges discovery science with early development, driving transformational medicines for autoimmune and inflammatory diseases.

The successful candidate leads cross-functional teams, shapes portfolio strategy, and accelerates first‑in‑human programs toward proof‑of‑concept, with strong executive presence and collaboration across discovery, translational